Uses of Glazymap

Glazymap drug has the main active ingredient Rabeprazol sodium hydrate with 20mg content and other excipients in sufficient quantity. This is a medicine for the treatment of gastrointestinal diseases such as active duodenal ulcer, gastroesophageal reflux disease and maintenance treatment in gastroesophageal reflux disease.

Rabeprazole drug of Glazymap causes inhibition of H +, K + - ATPase. At the same time, it exerts strong inhibitory effect on H+, K+ - ATPase prepared from gastric mucosa of pigs.
Active ingredients that inhibit gastric acid secretion:
Active ingredient Rabeprazole sodium inhibits gastric acid secretion stimulated by dibutyl cyclic AMP in the gastric glands of rabbits isolated in experiments. Rabeprazole sodium strongly inhibited gastric acid secretion stimulated by histamine or pentagastrin in dogs with chronic gastric fistula as well as gastric acid secretion under normal or histamine-stimulated conditions in rats in rats. experiment. Reversal of the anti-secretory activity of Rabeprazole sodium was faster and the increase in blood gastrin levels was lower with Rabeprazole sodium than with other proton pump inhibitors. Anti-ulcer activity:
In rats, the active ingredient rabeprazole sodium has been shown to have potent anti-ulcer prophylactic activity against a variety of ulcers and ameliorate experimental gastric mucosal lesions (cold-induced stress or due to water immersion, pyloric ligation, use of cysteine ​​or ethanol-HCl).

Glazymap is indicated for use in the following cases:
Treatment of active duodenal ulcer disease. Treatment of active benign gastric ulcer. Treatment of ulcerative or erosive gastroesophageal reflux disease (GORD). Treatment of mouth ulcers. Treatment of reflux esophagitis. Treatment of Zollinger-Ellison syndrome.

3.1. How to use Glazymap drug Glazymap drug is prepared in the form of film-coated tablets, suitable for oral use, Glazymap tablets should be swallowed whole, do not chew, crush or break the tablets.
3.2. Dosage of Glazymap For adults, the dose is 10mg/day, the dose can be increased to 20mg/day depending on the specific disease condition of each person. The average duration of duodenal ulcer treatment is 4 to 8 weeks, for gastric ulcer and reflux esophagitis, 6 to 12 weeks. Treatment of Zollinger-Ellison syndrome: The recommended starting dose is 60 mg once daily. The therapeutic dose may be increased to 100 mg once daily or 120 mg twice daily based on individual individual needs. You should continue to maintain it as clinically indicated by your doctor. For patients with renal and hepatic impairment: No dose adjustment is required. Treatment with children: The main drug Rabeprazole is not recommended for use in children. There is no experience in using the drug in this group of patients. Note that: The therapeutic dose as provided above is for reference only, as recommended by the manufacturer. The specific dose depends on the health condition and progress of the disease of each specific person. For a specific and appropriate therapeutic dose, you need to carefully consult your treating doctor or medical professional.
Currently there is no specific antidote for Rabeprazole overdose. Active ingredient Rabeprazole has a strong ability to bind to plasma proteins, therefore, hemodialysis is not performed. Similar to other overdose cases, the doctor will mainly treat symptoms and take appropriate supportive measures.
When you forget to take a dose, you need to take it as soon as you remember. However, if it is too close to the next dose, you should skip the missed dose and take your next dose at the scheduled time. You need to be careful not to use the drug with more than double the prescribed dose.

Undesirable effects that may be encountered during treatment with Glazymap include: fever, weakness, allergic reactions, chills, fatigue, pain in the chest below the sternum, stiff neck, sensitivity light, belching, abdominal distension, heaviness in the abdomen, digestive disorders, dry mouth, gastrointestinal bleeding, black stools, gallstones, ulcers of the oral mucosa, glossitis or pancreatitis.

The active ingredient Rabeprazole sodium causes a strong and prolonged inhibition of gastric acid secretion. Glazymap may interact with drugs that are absorbed depending on gastric pH. When Glazymap is used with Ketoconazole or Itraconazole, there can be a significant decrease in antifungal drug concentrations. Therefore, your treating physician can monitor your medical condition while taking the drug to determine if the therapeutic dose of Ketoconazole or Itraconazole needs to be adjusted when used concomitantly with medicines containing the active ingredient Rabeprazole. .

6.1. Contraindications of the drug Glazymap Glazymap drug is contraindicated in the following cases:
Contraindicated for people with sensitive or hypersensitivity to the main ingredient Rabeprazol sodium or any ingredient of the drug. Pregnant and lactating women. 6.2. Precautions when using Glazymap Long-term treatment, especially those who have been treated for more than one year, should be monitored regularly. There is a risk of cross-hypersensitivity between Glazymap and other proton pump inhibitors or benzimidazole derivatives. Glazymap tablets should be swallowed whole and should not be chewed or crushed. Rabeprazole-containing medicines are not recommended for use in children. The reason is that there is currently no experience using this drug in this group of people. Ability to drive and use machines: Based on the pharmacokinetics and adverse reactions data, it is unlikely that Glazymap will affect the ability to use machines or drive. However, if you feel sleepy while using Glazymap, you should not do tasks that require concentration such as driving or operating machinery. Pregnancy: There are no data on the safety of Glazymap during pregnancy. Lactation: It is not known whether rabeprazole is excreted in human milk. There are no studies on the use of Glazymap in lactating women. However, according to laboratory studies, rabeprazole is excreted in the milk of rats. Therefore, Glazymap should not be used by women who are breastfeeding. The active ingredient Glazymap is Rabeprazole sodium. It is a drug for the treatment of active duodenal ulcer, active benign gastric ulcer, gastroesophageal reflux disease and long-term maintenance treatment of gastroesophageal reflux disease.
Above is all information about Glazymap drug, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy Glazymap medicine to treat the disease at home, because there may be unwanted side effects on health.